Correlation of HER-2/neu Overexpression With Mammography and Age Distribution in Primary Breast Carcinomas

Academic Radiology

Volumn 13, Issue 10, 2006, Pages 1211-1218

  Seo, Bo Kyoung ^a   Pisano, Etta D ^b   Kuzimak, Cherie M ^b   Koomen, Marcia ^b   Pavic, Dag ^b   Lee, Yeonhee ^b   Cole, Elodia B ^b   Lee, Juneyoung ^c  

^a Korea University   (South Korea)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Korea University College of Medicine   (South Korea)

Author keywords

age distribution; Breast cancer; HER 2 gene; mammography

Indexed keywords

TRASTUZUMAB; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CALCIFICATION; BREAST CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONCOGENE NEU; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM PROTEINS; NORTH CAROLINA; PROGNOSIS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS; STATISTICS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 33748556244     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2006.06.015     Document Type: Article

References (26)

1. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: Correlation of relapse and survival with amplication of the HER-2/neu oncogene. Science 235 (1987) 177-182
2. Seshadro R., Figaira F.A., Horsfall D.J., et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11 (1993) 1936-1942
3. Walker R.A., Dearing S.J., and Brown L.A. Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast. Hum Pathol 30 (1999) 943-948
4. Evans A.J., Pinder S.E., Ellis I.O., et al., Nottingham Breast Team. Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Clin Radiol 49 (1994) 559-562
5. Karamouzis M.V., Likaki-Karatza E., Ravazoula P., et al. Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer 102 (2002) 86-90
6. Pegram M.D., Konecny G.E., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96 (2004) 739-749
7. Sawaki M., Ito Y., Tada K., Mizunuma N., et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori 90 (2004) 40-43
8. Konecny G., Pauletti G., Pegram M., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95 (2003) 142-153
9. Berger M.S., Locher G.W., Saurer S., et al. Correlation of c-erbB-2 gene amplification and protein expression human breast carcinoma with nodal status and nuclear grading. Cancer Res 48 (1988) 1238-1243
10. Taucher S., Rudas M., Gnant M., et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma?. Cancer 98 (2003) 2547-2553
11. Colleoni M., Rotmensz N., Robertson C., et al. Very young women (<35 years) with operable breast cancer: Features of disease at presentation. Ann Oncol 13 (2002) 273-279
12. Rajakariar R., and Walker R.A. Pathological and biological features of mammographically detected invasive breast carcinomas. Br J Cancer 71 (1995) 150-154
13. Tavassoli F.A. Infiltrating carcinoma: common and familiar special types. Pathology of the Breast. 2nd ed. (1999), McGraw-Hill Health Professions Division, Hong Kong 401-480
14. Bloom H.J.G., and Richardson W.W. Histologic grading and prognosis in breast cancer: A study of 1709 cases of which 359 have been followed for 15 years. Br J Cancer 2 (1957) 353-377
15. Le Doussal V., Tubiana-Hulin M., Friedman S., et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64 (1989) 1914-1921
16. Tavassoli F.A. Ductal intraepithelial neoplasia. Pathology of the breast. 2nd ed. (1999), McGraw-Hill Health Professions Division, Hong Kong 265-295
17. Yaziji H., Goldstein L.C., Barry T.S., et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 (2004) 1972-1977
18. Field A.S., Chamberlain N.L., Tran D., and Morey A.L. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridization. Pathology 33 (2001) 278-282
19. ®)-Mammography. 4th ed. (2003), American College of Radiology, Reston
20. Altman DG D.G. Practical Statistics for Medical Research (1996), Chapman Hall, London 266-268
21. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
22. Bonnier P., Romai S., Charpin C., et al. Age as a prognostic factor in breast cancer: Relation to pathologic and biologic features. Int J Cancer 17 (1995) 138-144
23. Bertheau P., Steinberg S.M., Cowan K., and Merino M.J. Breast cancer in young women: Clinicopathologic correlation. Semin Diagn Pathol 16 (1999) 248-256
24. National Cancer Policy Board. Saving women's lives: strategies for improving breast cancer detection and diagnosis (2005), National Academy of Sciences, Washington, DC 37-62
25. Fletcher S.W., and Elmore J.G. Mammographic screening for breast cancer. N Engl J Med 348 (2003) 1672-1680
26. Lagios M.D., Margolin F.R., Westdahl P.R., and Rose M.R. Mammographically detected duct carcinoma in situ: Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63 (1989) 618-624